Search
50 results for www.fiercepharma.com:
Cabometyx study ends early after researchers see 'dramatic' benefits in neuroendocrine tumors, Exelixis says - FiercePharma
fiercepharma.comSubmitted by fiercepharma5012 in business
It's not always a good thing when a drug developer stops a cancer trial